News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)